Tempest Therapeutics reports FY2024 net loss $41.8M, cash $30.3M; amezalpat gets FDA designations

Tempest Therapeutics, Inc.

Net loss $41.8M ($1.50/share) vs $29.5M ($1.91/share) in 2023; R&D spend rose to $28.5M.
Cash and equivalents $30.3M at Dec 31, 2024, down from $39.2M; ATM proceeds of $28.6M partially offset burn.
Amezalpat (TPST-1120) received FDA Orphan Drug and Fast Track status for first-line HCC.
Agreement signed with Roche to support pivotal Phase 3 trial of amezalpat + atezolizumab + bevacizumab in HCC.
FDA cleared Phase 2 trial of TPST-1495 for familial adenomatous polyposis; data expected in 2026.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0000950170-25-046055
form_type: 8-K
ticker: TPST
cik: 0001544227
company_name: Tempest Therapeutics, Inc.
filed_at: 2025-03-27T23:59:59+00:00
discovered_at: 2026-05-14T18:03:03.958266+00:00
generated_at: 2026-05-24T03:53:43.208938+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0000950170-25-046055
json_url: https://secwatch.observer/filing/0000950170-25-046055.json
markdown_url: https://secwatch.observer/filing/0000950170-25-046055.md
text_url: https://secwatch.observer/filing/0000950170-25-046055.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1544227/000095017025046055/0000950170-25-046055-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1544227/000095017025046055/tpst-20250327.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0000950170-25-046055

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.